News Search Results
Aug 05, 2026, 08:36 ET AD/PD™ 2027, Organized by Kenes Group, Issues Global Call for Abstracts on Alzheimer's, Parkinson's, and Related Disorders
consideration are: β-amyloid diseases, tauopathies, α-synucleinopathies, TDP-43, TMEM106B and C9orf72-related diseases, vascular diseases, prion diseases, Huntington's and other neurodegenerative diseases, demyelinating diseases, lysosomal storage diseases, psychiatric symptoms in neurodegenerative diseases, patient
More news about: Kenes Group
Aug 03, 2026, 11:15 ET Huntington Bank Names Blake Absher Central Texas Division President
Texas banking veteran to lead Huntington's expansion across Central Texas, including Austin, San Antonio, Waco and Bryan/College StationAUSTIN, Texas, Aug. 3, 2026 /PRNewswire/ -- The Huntington
More news about: Huntington Bank
Jul 30, 2026, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
francs)cUHDRS: Composite Unified Huntington's Disease Rating ScaleDMD: Duchenne muscular dystrophyFA: Friedreich's ataxiaFDA: US Food and Drug AdministrationGAAP: Generally Accepted Accounting PrinciplesHD: Huntington's diseaseNDA: New Drug ApplicationnmDMD:
More news about: PTC Therapeutics, Inc.
Jul 30, 2026, 16:01 ET Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
$90INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington's disease.R&D guidance reflects the continued advancement of the Company's pre-clinical and clinical portfolio including the Phase 3
More news about: Neurocrine Biosciences, Inc.
Jul 30, 2026, 16:00 ET Huntington Bank Commits $80 Billion to Support Affordable Housing, Small Businesses and Local Communities
grow, neighborhoods become more vibrant and families gain access to opportunities. Huntington's Community Plan demonstrates how intentional investment can help drive meaningful outcomes."This plan builds on Huntington's prior Community plans and has delivered nearly 270,000 loans totaling $37.8 billion
More news about: Huntington Bank
Jul 23, 2026, 16:05 ET Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust
More news about: Neurocrine Biosciences, Inc.
Jul 23, 2026, 06:15 ET Huntington Bancshares Incorporated Reports 2026 Second-Quarter Earnings
reconciliations to the comparable GAAP financial measure included in this release or Huntington's Quarterly Financial Supplement.Conference Call / Webcast InformationHuntington's senior management will host an earnings conference call on July 23, 2026,
More news about: Huntington Bancshares Incorporated
Jul 21, 2026, 16:05 ET Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust
More news about: Neurocrine Biosciences, Inc.
Jul 20, 2026, 13:30 ET Huntington Bank Opens First Branch in Summerville
Located at 103 Station St., the newly built, freestanding branch marks Huntington's fourth full-service branch in South Carolina. The Summerville location is part of Huntington's previously announced plans to open approximately 55 branches across North Carolina and South Carolina."The
More news about: Huntington Bank
Jul 20, 2026, 10:59 ET Huntington Bank Named the United States' Best Digital Bank for Consumers
Prestigious global recognition from Euromoney highlights Huntington's people-first, digitally powered approach to helping customers manage their financial livesCOLUMBUS, Ohio, July 20, 2026 /PRNewswire/
More news about: Huntington Bank
Jul 14, 2026, 08:36 ET Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
SKY-0515 may offer Huntington's patients a type of therapy they have long deserved, in a convenient daily pill."SKY-0515 has demonstrated excellent central nervous system exposure and has been generally safe and well tolerated across dose levels studied.Huntington's disease is a rare, hereditary,
More news about: Skyhawk Therapeutics
Jul 14, 2026, 08:17 ET Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
offer Huntington's patients a type of therapy they have long deserved, in a convenient daily pill."SKY-0515 has demonstrated excellent central nervous system exposure and has been generally safe and well tolerated across dose levels studied.Huntington's disease
More news about: Skyhawk Therapeutics
Jul 14, 2026, 08:00 ET Huntington Securities, Inc. Launches Equity Research Platform
Gaugler has more than 20 years of experience as a senior research analyst on the sell side.The expansion into equity research follows Huntington's acquisition of three strategic business units and select hiring of equity professionals from Janney Montgomery Scott. The acquisition, which closed
More news about: Huntington Bancshares Incorporated
Jul 09, 2026, 16:01 ET Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well
More news about: Neurocrine Biosciences, Inc.
Jul 08, 2026, 17:00 ET Huntington Bancshares Incorporated Announces Second Quarter 2026 Earnings Call Details
webcast in the Investor Relations section of Huntington's website or through a dial-in telephone number at (877) 407-8029 or (201) 689-8029; conference ID # 13761371.A replay of the webcast will be archived in the Investor Relations section of Huntington's website. A telephone replay will be available
More news about: Huntington Bancshares Incorporated
Jul 08, 2026, 10:31 ET Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight
neuropsychiatric adverse events, including depression, somnolence, anxiety, and akathisia. Supported by encouraging safety and efficacy data from Huntington's disease studies, the candidate is being developed as a potential next-generation treatment for tardive dyskinesia, with the potential to improve
More news about: DelveInsight Business Research, LLP
Jul 01, 2026, 16:05 ET Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well
More news about: Neurocrine Biosciences, Inc.
Jul 01, 2026, 08:50 ET Skyhawk Therapeutics veröffentlicht die Ergebnisse der cUHDRS-Unterkomponenten nach zwölf Monaten aus seiner klinischen Phase-1/2-Studie mit SKY-0515 bei der Huntington-Krankheit
Zwölfmonats-Zwischenanalyse der Daten seiner klinischen Phase-1/2-Studie zur Bewertung von SKY-0515 an, einem oralen Prüfpräparat zur Behandlung der Huntington-Krankheit (Huntington's Disease, HD).
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:05 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
data from the twelve-month interim analysis of data from its Phase 1/2 clinical trial evaluating SKY-0515, an oral investigational treatment for Huntington's disease (HD).
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:00 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
data from the twelve-month interim analysis of data from its Phase 1/2 clinical trial evaluating SKY-0515, an oral investigational treatment for Huntington's disease (HD).
More news about: Skyhawk Therapeutics
Jun 25, 2026, 10:31 ET Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight
Huntington's Disease Market ReportHuntington's Disease Patient Population ForecastHuntington's Disease Therapeutics Market SizeHuntington's Disease Pipeline AnalysisHuntington's Disease Market Size and TrendsHuntington's Disease
More news about: DelveInsight Business Research, LLP
Jun 18, 2026, 10:00 ET LiftHigh Crane Doubles Credit Facility and Announces New Central Texas Branch
execute their growth strategy across Texas. We are proud to partner with proven operators in this space. Our relationship with LiftHigh reflects Huntington's broader commitment to expanding our presence across the state. We look forward to supporting their continued momentum as they enter their next phase
More news about: LiftHigh Crane & Rigging, LLC
Jun 15, 2026, 16:10 ET Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 16:05 ET Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well
More news about: Neurocrine Biosciences, Inc.
Jun 15, 2026, 08:35 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well
More news about: Neurocrine Biosciences, Inc.